4.7 Article

Characterization of WWOX inactivation in murine mammary gland development

Journal

JOURNAL OF CELLULAR PHYSIOLOGY
Volume 228, Issue 7, Pages 1391-1396

Publisher

WILEY
DOI: 10.1002/jcp.24310

Keywords

-

Funding

  1. Israeli Science Foundation grant (ISF) [08-1331]
  2. EU-FP7 Marie Curie Re-integration
  3. Israeli Cancer Research Funds (ICRF)
  4. NIDDK [NIH R01 DK079217]

Ask authors/readers for more resources

The WW domain-containing oxidoreductase (WWOX) is commonly inactivated in multiple human cancers, including breast cancer. Wwox null mice die prematurely precluding adult tumor analysis. Nevertheless, aging Wwox-heterozygous mice at C3H genetic background develop higher incidence of mammary tumors. We recently generated a Wwox conditional knockout mouse in which loxp sites flank exon 1 in the Wwox allele and showed that total ablation of WWOX in these mice resembles that of conventional targeting of Wwox. Here, we report the characterization of WWOX ablation in mouse mammary gland using MMTV-Cre transgenic line. We demonstrated that WWOX ablation leads to impaired mammary ductal growth. Moreover, targeted deletion of WWOX is associated with increased levels of fibronectin, a component of the extracellular matrix. In addition, we showed that shRNA knockdown of WWOX in MCF10A breast epithelial cells dramatically increased fibronectin and is associated with enhanced cell survival and impaired growth in three-dimensional culture Matrigel assay. Taken together our results are consistent with a critical role for WWOX in normal breast development and tumorigenesis. J. Cell. Physiol. 228: 13911396, 2013. (c) 2012 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available